In a pristane‐induced systemic lupus erythematosus (SLE) mouse model, pharmacological inhibition of PCSK9 significantly attenuated systemic inflammation, as evidenced by a 40–50% reduction in proinflammatory cytokines (IL‐17, TNF‐α) and increase in anti‐inflammatory TGF‐β levels (p < 0.01). Here, TGFB1 is linked to systemic lupus erythematosus.